The University of Chicago Header Logo

Connection

George Bakris to Risk Assessment

Back to Details
This is a "connection" page, showing publications George Bakris has written about Risk Assessment.
George Bakris
Connection Strength
1.924
Risk Assessment
  1. Cardiovascular protection for all individuals at high risk: evidence-based best practice. Clin Res Cardiol. 2008 Oct; 97(10):713-25.
    View in: PubMed
    Score: 0.192
  2. Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial. Cardiovasc Diabetol. 2021 09 14; 20(1):187.
    View in: PubMed
    Score: 0.119
  3. Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial. Clin Res Cardiol. 2021 Jul; 110(7):1006-1019.
    View in: PubMed
    Score: 0.110
  4. Similarities and Differences Between the ACC/AHA and ESH/ESC Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Circ Res. 2019 03 29; 124(7):969-971.
    View in: PubMed
    Score: 0.100
  5. Consequences of Overinterpreting Serum Creatinine Increases when Achieving BP Reduction: Balancing Risks and Benefits of BP Reduction in Hypertension. Clin J Am Soc Nephrol. 2018 01 06; 13(1):9-10.
    View in: PubMed
    Score: 0.091
  6. On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults With Isolated Systolic Hypertension. Hypertension. 2017 02; 69(2):220-227.
    View in: PubMed
    Score: 0.086
  7. Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. J Clin Hypertens (Greenwich). 2016 Apr; 18(4):299-307.
    View in: PubMed
    Score: 0.081
  8. Renal Denervation After SYMPLICITY HTN-3: Where Do We Go? Can J Cardiol. 2015 May; 31(5):642-8.
    View in: PubMed
    Score: 0.074
  9. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. Am J Cardiol. 2013 Jul 15; 112(2):255-9.
    View in: PubMed
    Score: 0.066
  10. Blood pressure targets for patients with diabetes or kidney disease. Curr Hypertens Rep. 2011 Dec; 13(6):452-5.
    View in: PubMed
    Score: 0.060
  11. Pediatrics: Masked hypertension: a risk factor in children with CKD. Nat Rev Nephrol. 2010 Mar; 6(3):132-4.
    View in: PubMed
    Score: 0.053
  12. Hypertension goals in advanced-stage kidney disease. Clin J Am Soc Nephrol. 2009 Dec; 4 Suppl 1:S92-4.
    View in: PubMed
    Score: 0.052
  13. Risk factor assessment for new onset diabetes: literature review. Diabetes Obes Metab. 2009 Mar; 11(3):177-87.
    View in: PubMed
    Score: 0.047
  14. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008 Apr; 121(4):332-40.
    View in: PubMed
    Score: 0.047
  15. Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to action. J Hum Hypertens. 2008 Jan; 22(1):63-70.
    View in: PubMed
    Score: 0.045
  16. An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. Am J Nephrol. 2006; 26(3):268-75.
    View in: PubMed
    Score: 0.041
  17. Albuminuria and cardiovascular risk. Heart Fail Clin. 2006 Jan; 2(1):53-9.
    View in: PubMed
    Score: 0.040
  18. Obesity and insulin resistance as risk factors for chronic kidney disease. J Cardiometab Syndr. 2006; 1(3):209-14; quiz 215-6.
    View in: PubMed
    Score: 0.040
  19. Clinical importance of microalbuminuria in diabetes and hypertension. Curr Hypertens Rep. 2004 Oct; 6(5):352-6.
    View in: PubMed
    Score: 0.037
  20. Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals. Postgrad Med. 2002 Oct; 112(4):73-4, 77-80, 83-4.
    View in: PubMed
    Score: 0.032
  21. Association of Arterial Stiffness With Kidney Function Among Adults Without Chronic Kidney Disease. Am J Hypertens. 2020 11 03; 33(11):1003-1010.
    View in: PubMed
    Score: 0.028
  22. Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus. Am Heart J. 2020 11; 229:40-51.
    View in: PubMed
    Score: 0.028
  23. Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. J Am Heart Assoc. 2020 01 07; 9(1):e012797.
    View in: PubMed
    Score: 0.026
  24. Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). Am J Cardiol. 2019 02 01; 123(3):382-391.
    View in: PubMed
    Score: 0.024
  25. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation. 2018 10 09; 138(15):1537-1550.
    View in: PubMed
    Score: 0.024
  26. The Appropriate Blood Pressure Control in Diabetes (ABCD) Trial. J Hum Hypertens. 1998 Sep; 12(9):653-5.
    View in: PubMed
    Score: 0.024
  27. Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. J Am Heart Assoc. 2018 05 16; 7(11).
    View in: PubMed
    Score: 0.024
  28. Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. Am J Kidney Dis. 2018 06; 71(6):851-865.
    View in: PubMed
    Score: 0.023
  29. Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. Clin J Am Soc Nephrol. 2018 03 07; 13(3):398-405.
    View in: PubMed
    Score: 0.023
  30. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. J Am Heart Assoc. 2018 01 04; 7(1).
    View in: PubMed
    Score: 0.023
  31. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension. 2016 09; 68(3):606-13.
    View in: PubMed
    Score: 0.021
  32. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. Eur Heart J Cardiovasc Pharmacother. 2016 07; 2(3):200-5.
    View in: PubMed
    Score: 0.020
  33. Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. Am Heart J. 2016 May; 175:18-27.
    View in: PubMed
    Score: 0.020
  34. Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. Atherosclerosis. 2015 Dec; 243(2):553-9.
    View in: PubMed
    Score: 0.020
  35. Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension. J Am Soc Hypertens. 2015 Nov; 9(11):845-54.
    View in: PubMed
    Score: 0.019
  36. Effects of antihypertensive treatment in Asian populations: a meta-analysis of prospective randomized controlled studies (CARdiovascular protectioN group in Asia: CARNA). J Am Soc Hypertens. 2014 Feb; 8(2):103-16.
    View in: PubMed
    Score: 0.017
  37. Association of BP variability with mortality among African Americans with CKD. Clin J Am Soc Nephrol. 2013 May; 8(5):731-8.
    View in: PubMed
    Score: 0.016
  38. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2012 Jan 09; 172(1):41-7.
    View in: PubMed
    Score: 0.015
  39. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012 Mar; 81(6):568-76.
    View in: PubMed
    Score: 0.015
  40. Isolated diastolic hypotension and incident heart failure in older adults. Hypertension. 2011 Nov; 58(5):895-901.
    View in: PubMed
    Score: 0.015
  41. Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease. J Am Soc Nephrol. 2010 Dec; 21(12):2131-42.
    View in: PubMed
    Score: 0.014
  42. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med. 2009 Sep 28; 169(17):1587-94.
    View in: PubMed
    Score: 0.013
  43. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press. 2008; 17(1):7-17.
    View in: PubMed
    Score: 0.011
  44. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007 Jun 11; 167(11):1122-9.
    View in: PubMed
    Score: 0.011
  45. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S154-65.
    View in: PubMed
    Score: 0.008
  46. The rationale and design of the AASK cohort study. J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S166-72.
    View in: PubMed
    Score: 0.008
  47. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003 Mar 10; 163(5):525-41.
    View in: PubMed
    Score: 0.008
  48. Roundtable discussion: problems in the management of hypertension. J Clin Hypertens (Greenwich). 2002 May-Jun; 4(3):207-13.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.